
LUTATHERA® Product Monograph
Recently issued: dated September 9, 2022.
For Canadian healthcare professionals only
For Canadian healthcare professionals only
Welcome to the LUTATHERA® Resource HUB – a repository of LUTATHERA® tools for you and your patients.
We invite you to view or download any of the tools listed below.
Resources will be updated on the LUTATHERA® Resource HUB – please check back periodically for the latest tools!
* Comparative clinical significance is unknown.
LUTATHERA (lutetium (177Lu) oxodotreotide) is indicated for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.
Recently issued: dated September 9, 2022.
A slide deck covering LUTATHERA® mechanism of action, clinical studies, safety profile and dosing information.
A concise brochure that provides an overview of the NETTER-1 trial.
An illustrated booklet that includes information relevant to patients such as step-by-step dosing and administration and other information relevant to patients.
A printable card for Information related to the procedure date and time.
LUTATHERA® (lutetium (177Lu) oxodotreotide) is indicated for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.
Radiation Contamination: LUTATHERA® can contribute to a patient’s overall long-term exposure to radiation, which is associated with increased risk of cancer.
Acute and chronic renal toxicity: Can develop gradually during and after treatment. Patients should be advised to urinate frequently during and after administration.
Myelodysplastic syndrome and acute leukemia: Have both been observed after treatment. Patients over 70 years old, those with impaired renal function, pre-existing cytopenias, or prior exposure to chemo or radiation therapy may be at increased risk.
Consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for important information relating to adverse reactions, drug interactions, and dosing and administration which has not been discussed in this piece.
The Product Monograph is also available by emailing medinfo.canada@novartis.com or by calling 1-800-363-8883.
References: